ABL Bio Inc - Asset Resilience Ratio

Latest as of March 2026: 0.69%

ABL Bio Inc (298380) has an Asset Resilience Ratio of 0.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩2.05 Billion

≈ $1.39 Million USD Cash + Short-term Investments

Total Assets

₩298.13 Billion

≈ $202.04 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how ABL Bio Inc's Asset Resilience Ratio has changed over time. Check 298380 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down ABL Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 298380 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩2.05 Billion	0.69%
Total Liquid Assets	₩2.05 Billion	0.69%

Asset Resilience Insights

Limited Liquidity: ABL Bio Inc maintains only 0.69% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

ABL Bio Inc Industry Peers by Asset Resilience Ratio

Compare ABL Bio Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
Galapagos NV F:GXEA	Biotechnology	86.45%
Nanobiotix S.A PA:NANO	Biotechnology	53.40%
Chengdu Easton Biopharmaceuticals Co Ltd SHG:688513	Biotechnology	34.30%
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	Biotechnology	4.35%

Annual Asset Resilience Ratio for ABL Bio Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for ABL Bio Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.05%	₩2.96 Billion ≈ $2.01 Million	₩280.93 Billion ≈ $190.39 Million	-59.58pp
2024-12-31	60.64%	₩140.66 Billion ≈ $95.32 Million	₩231.98 Billion ≈ $157.21 Million	+16.21pp
2023-12-31	44.43%	₩71.15 Billion ≈ $48.22 Million	₩160.14 Billion ≈ $108.53 Million	+2.14pp
2022-12-31	42.29%	₩78.32 Billion ≈ $53.07 Million	₩185.18 Billion ≈ $125.49 Million	-24.39pp
2021-12-31	66.68%	₩43.65 Billion ≈ $29.58 Million	₩65.45 Billion ≈ $44.36 Million	-3.78pp
2020-12-31	70.47%	₩70.39 Billion ≈ $47.70 Million	₩99.89 Billion ≈ $67.70 Million	-22.81pp
2019-12-31	93.27%	₩133.29 Billion ≈ $90.33 Million	₩142.90 Billion ≈ $96.84 Million	+10.41pp
2018-12-31	82.86%	₩139.92 Billion ≈ $94.82 Million	₩168.87 Billion ≈ $114.44 Million	+37.84pp
2017-12-31	45.02%	₩9.17 Billion ≈ $6.21 Million	₩20.37 Billion ≈ $13.80 Million	-25.89pp
2016-12-31	70.91%	₩5.34 Billion ≈ $3.62 Million	₩7.53 Billion ≈ $5.10 Million	--

pp = percentage points

About ABL Bio Inc

KQ:298380 Korea Biotechnology

Market Cap

$3.24 Billion

₩4.77 Trillion KRW

Market Cap Rank

#4696 Global

#107 in Korea

Share Price

₩86600.00

Change (1 day)

+3.96%

52-Week Range

₩60800.00 - ₩245500.00

All Time High

₩245500.00